This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The 17th edition of CPHI & PMEC India, organised by Informa Markets in India opened its doors at the India Expo Centre, Greater Noida, Delhi-NCR, showcasing the robust potential of India’s pharmaceutical industry. Projections indicate exports will soar to $130 billion by 2030 and $450 billion by 2047. With exports nearing $27.84
India’s pharmaceutical industry is a global powerhouse. It is already a massive $50 billion market and is projected to grow to $130 billion by 2030. India makes 60 per cent of the world’s vaccines and 20 per cent of the world’s generic drugs. Infections and diseases once easy to treat become dangerous.
The expo enjoys support from key industry associations such as Bulk Drug Manufacturing Association (BDMA), Federation of Pharma Entrepreneurs (FOPE), Karnataka Drugs and PharmaceuticalsManufacturers’ Association (KDPMA), Organisation of Pharmaceutical Producers of India (OPPI), and Pharmaceutical Export Promotion Council (Pharmexcil).
The COVID-19 pandemic has further elevated the significance of this industry, spotlighting India’s role as a major global player in vaccine production and pharmaceutical R&D. Together, this has led to a surge in real estate demand that is likely to reach approximately 96 million sq ft by 2030 (1).
Given this dependence on foreign manufacturers, the African Union made regional production a central pillar of its New Public Health Order, and partnerships that support African-produced medicines, vaccines, and other medical products, are central to their efforts. But PEPFAR is looking to change how it does business.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content